



SERVICIO DE HEMATOLOGIA Y HEMOTERAPIA
HOSPITAL UNIVERSITARIO DE LA PRINCESA - MADRID

PRINCIPALES PUBLICACIONES CIENTIFICAS EN REVISTAS INTERNACIONALES . ACTUALIZACIÓN DICIEMBRE 2.011

INDEXADAS EN PUBMED

AÑO 2.011

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MA, Martínez-López J, Mateos MV, Cibeira MT, Cerdán L, Oriol A, Terol MJ, Echeveste MA, de Paz R, de Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Sureda A, Gorosquieta A, **Alegre A**, Martín A, Hernández MT, Lahuerta JJ, Bladé J, San Miguel JF.

Blood. 2011 Nov 29. [Epub ahead of print]

Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. **Alegre A, Aguado B**, Giraldo P, Ríos E, Cánovas A, Ibáñez A, Castillo I, Hernández MT, Oriol A, Palomera L, Rodríguez JN, García FL, Calvo JM, Martínez-Chamorro C, de la Serna J, Lahuerta JJ. **International Journal of Hematology**. 2011 Mar; 93(3):351-60

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease Rosinol L, Garcia-Sanz R, Lahuerta JJ, Hernandez M, Granell M, de la Rubia J, Oriol A, Hernandez B, Rayon C, Navarro I, Garcia-Ruiz JC, Besalduch J, Gardella S, Lopez J, Diaz-Mediavilla J, **Alegre A**, San Miguel J, Blade J. **Haematologica**. 2011 Nov 4. [Epub ahead of print]

Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia Bustos A, Alvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, Lázaro M, de Segovia JM, Gasquet JA, **Alegre A**; on behalf of the RADAR Study Group.

Curr Med Res Opin. 2011 Nov 23. [Epub ahead of print]

Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. Dimopoulos MA, Terpos E, Goldschmidt H, **Alegre A**, Mark T, Niesvizky R. **The Oncologist**. 2011, Accepted. In Press

Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Aurelia Bustos, Miguel Ángel Cruz, Pedro Miguel Aramburo , Francisco Carabantes, Nieves Díaz , Jesús Florián , Martín Lázaro , José María Martín de Segovia , José Antonio Gasquet and **Adrián Alegre** on behalf of the RADAR Study Group. **Supportive Care in Cancer**. 2011.

Joaquín Martínez-López , Joan Bladé , MV Mateos , Carlos Grande , **Adrián Alegre** et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. **Blood**, 2011. Jul 21;118(3):529-34.

Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. Calvo-Villas JM, **Alegre A**, Calle C, Hernández MT, García-Sánchez R, Ramírez G; GEM-PETHEMA/Spanish Myeloma Group, Spain. **Eur J Haematol**. 2011 Sep;87(3):281-4.

Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. Sanchez-Gonzalez B, Peñalver FJ, Medina A, Guillén H, Calleja M, Gironella M, **Arranz R**, Sebastian E, de Oña R, Cánovas A, de la Fuente I, Grande C, Sancho JM, Perez R, Domingo E, Lopez-Lorenzo JL, Prieto E, Panizo C, Gorosquieta A, Perez I, Cervera JM, Marin M, Mencha C, Ramila E, Salar A. **Leuk Res**. 2011 Dec 7. [Epub ahead of print]

Sureda A, Canals C, **Arranz R**, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcarcel D, Besalduch J, Duarte R, Leon A, Pascual MJ, **García-Noblejas A**, Lopez Corral L, Xicoy B, Sierra J, Schmitz N. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/ Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Haematologica. 2011 Oct 11. [Epub ahead of print]

The role of iron in tumour cell proliferation. **Steegmann-Olmedillas, JL**. Clin Transl Oncol, 2011. 13(2): p. 71-6.

Functional profile of cytomegalovirus (CMV)-specific CD8(+) T cells and kinetics of NKG2C(+) NK Cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients. Muñoz-Cobo B, Solano C, Benet I, Costa E, Remigia MJ, **de la Cámara R**, Nieto J, López J, Amat P, **García-Noblejas A**, Bravo D, Clari MÁ, Navarro D.

J Med Virol. 2012 Feb;84(2):259-67. doi: 10.1002/jmv.22254.

Aguilar-Guisado M, Jiménez-Jambrina M, Espigado I, Rovira M, Martino R, Oriol A, Borrell N, Ruiz I, Martín-Dávila P, **de la Cámara R**, Salavert M, de la Torre J, Cisneros JM; on behalf of Spanish Network for Research in Infectious Diseases.

Clin Transplant. 2011 Nov;25(6)

Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. Ruiz-Camps I, Len O, **de la Cámara R**, Gurguí M, Martino R, Jarque I, Barrenetxea C, Díaz de Heredia C, Batlle M, Rovira M, de la Torre J, Torres A, Aguilar M, Espigado I, Martín-Dávila P, Bou G, Borrell N, Aguado JM, Pahissa A; Spanish Network for Research on Infection in Transplantation (RESITRA/REIPI). Spain. **Antivir Ther**. 2011;16(7):951-7.

Pneumocystis jirovecii pneumonia as first manifestation of late relapse angioimmunoblastic T-cell lymphoma. **García-Noblejas A**, Velasco A, **García-León N**, **Cananta-Ortiz J**, **Steegmann JL**

Leuk Res. 2011 Sep;35(9):e143-4. Epub 2011

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Giles FJ, Rosti G, Beris P, Clark RE, le Coutre P, Mahon FX, **Steegmann JL**, Valent P, Saglio G: **Expert Rev Hematol** 2010, 3(6):665-673.

Cytogenetic risk stratification in chronic myelomonocytic leukemia. Such E, Cervera J, Costa D, Solé F, Vallespi T, Luño E, Collado R, Calasanz MJ, Hernández-Rivas JM, Cigudosa JC, Nomdedeu B, Mallo M, Carbonell F, Bueno J, Ardanaz MT, Ramos F, Tormo M, Sancho-Tello R, Cañizo CD, **Gómez V**, Marco V, Xicoy B, Bonanad S, Pedro C, Bernal T, Sanz GF. **Haematologica**. 2011 Mar; 96(3):375-83.

Reconstitution of CMV pp65 and IE-1-specific IFN- γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. Tormo N, Solano C, Benet I, Nieto J, de la Cámara R, López J, **García-Noblejas A**, Muñoz-Cobo B, Costa E, Clari MA, Hernández-Boluda JC, Remigia MJ, Navarro D. **Bone Marrow Transplant**. 2011 Jan 17.

Effect of Cytomegalovirus (CMV) Serostatus on the Incidence and Virological Features of Active CMV Infection in Allogeneic Stem Cell Transplant Recipients B. Muñoz-Cobo, C Solano, I Benet, E Costa, MJ Remigia, R de la Cámara, J Nieto, J López, P Amat, A. Garcia-Noblejas, D Bravo, and D Navarro.. **Clin Infect Disease** 2011

Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations Maria Castella, Roser Pujol, Elsa Callén, Juan P. Trujillo, José A. Casado, Hans Gille, Francis P. Lach, Arleen D. Auerbach, Detlev Schindler, Javier Benítez, Beatriz Porto, Teresa Ferro, Arturo Muñoz, Julián Sevilla, Luis Madero, Elena Cela, Cristina Beléndez, Cristina Díaz de Heredia, Teresa Olivé, José Sánchez de Toledo, Isabel Badell, Montserrat Torrent, Jesús Estella, Ángeles Dasí, Antonia Rodríguez-Villa, Pedro Gómez, José Barbot, María Tapia, Antonio Molinés, **Ángela Figuera**, Juan A. Bueren, and Jordi Surrallés **Blood** 2011 117:3759-3769

AÑO 2.010

Clonal evolution in patients with chronic lymphocytic leukemia. **Loscertales J, Arranz E**, Sanz MA, Blas C, Gil-Fernández JJ, Burgaleta C, Alegre A. **Leuk Lymphoma**. 2010 Jun; 51(6):1142-3.

Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group and the PETHEMA group. García-Sanz R, **Alegre A**, Capote FJ, Hernández JM, Rosiñol L, Rubia Jde L, Sureda A, Arriba F, Bargay J, Díaz Mediavilla J, García-Laraña J, Lahuerta JJ, Mateos MV, Prósper F, San Miguel J, Bladé J. *Med Clin (Barc)*. 2010 Mar 6; 134(6):268-78.

Mid term results after bone marrow laser revascularization for treating refractory angina. Reyes G, Allen KB, Álvarez P, **Alegre A, Aguado B**, Olivera M, Caballero P, Rodríguez J, Duarte J. **BMC Cardiovasc Disord**. 2010 Sep 17; 10:42.

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Dimopoulos M, **Alegre A**, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, Masliak Z, Reece D, Olesnyckyj M, Yu Z, Weber DM. **Cancer**. 2010 Aug 15; 116(16):3807-14.

Busulfan 12 mg/kg plus melphalan 140 mg/m² versus melphalan 200 mg/m² as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study Lahuerta JJ, Mateos MV, Martínez-López J, Grande C, de la Rubia J, Rosiñol L, Sureda A, García-Laraña J, Díaz-Mediavilla J, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Oriol A, Escoda L, García-Frade J, Rivas-González C, **Alegre A**, Bladé J, San Miguel JF.. **Haematologica**. 2010 Nov; 95(11):1913-20

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials .Piñana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Díez-Martín JL, Vázquez L, **Arranz R**, Tomás JF, Sampol A, Solano C, Delgado J, Sierra J, Caballero D; GELTAMO Group.. **Haematologica**. 2010 Jul; 95(7):1176-82.

A molecular risk score based on four functional pathways for advanced classical Hodgkin lymphoma. Sánchez-Espiridión B, Montalbán C, López A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R, Rodríguez J, Cánovas A, Camarero C, Canales M, Alves J, **Arranz R**, Acevedo A, Salar A, Serrano S, Bas A, Moraleda JM, Sánchez-Godoy P, Burgos F, Rayón C, Fresno MF, García Laraña J, García-Cosío M, Santonja C, López JL, Llanos M, Mollejo M, González-Carrero J, Marín A, Forteza J, García-Sanz R, Tomás JF, Morente MM, Piris MA, García JF. **Blood**. 2010 May 17 Aug 26;116(8):e12-7

Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation Duarte RF, Canals C, Onida F, Gabriel IH, **Arranz R**, Arcese W, Ferrant A, Kobbe G, Narni F, Deliliers GL, Olavarria E, Schmitz N, Sureda A.. **J Clin Oncol**. 2010 Aug 9

Loscertales J, Arranz E, Sanz MA, Blas C, Gil-Fernández JJ, Burgaleta C, Alegre A. Clonal evolution in patients with chronic lymphocytic leukemia. **Leukemia Lymphoma**. 2010 Jun; 51(6):1142-3.
PMID:19295545[PubMed - indexed for MEDLINE]

Related citations

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA; IRIS Investigators: **Steegmann JL**: **Leukemia**. 2009 Jun; 23(6):1054-61. Epub 2009 Mar 12. Erratum in: **Leukemia**. 2010 May; 24(5):1102.

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, **Loscertales J**, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI.. **J Clin Oncol**. 2010 Apr 1; 28(10):1756-65

Effect of FCGR2A and FCGR3A variants on CLL outcome Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G, Dufour A, Zhi J, Robak T, Moiseev SI, Dmoszynska A, Solal-Céligny P, Warzocha K, **Loscertales J**, Catalano J, Afanasiev BV, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Wenger MK, Weisser M.. **Blood**. 2010 Aug 12.

Targeting migratory and pro-survival cascades induced by the homeostatic chemokines CCL19 and CCL21 for therapy of B-chronic lymphocytic leukaemia. Cuesta-Mateos C, López-Giral S, Alfonso-Pérez M, **Gómez García de Soria V, Loscertales J**, Muñoz-Calleja C. **Experimental Hematology**. 2010; 38(9):756-764

Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFN γ CD8 $^{+}$ and CD4 $^{+}$ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients Tormo N, Solano C, Benet I, Clari MA, Nieto J, de la Cámara R, López J, López-Aldeguer N, Hernández-Boluda JC, Remigia MJ, **García-Noblejas A**, Gimeno C, Navarro D.. **Bone Marrow Transplant**. 2010 Mar; 45(3):543-9.

An Assessment of the Effect of Human Herpesvirus 6 Replication on Active Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation. Tormo N, Solano C, **de la Cámara R, García-Noblejas A, Cardeñoso L**, Angeles Clari M, Nieto J, López J, Hernández-Boluda JC, Remigia MJ, Benet I, Navarro D. **Biol Blood Marrow Transplant**. 2010 May; 16(5):653-61.

Unrelated Transplants For Poor Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis And Study Of The Impact Hematopoietic Graft Source. Ferrá C, Sanz J, **de La Cámara R**, Sanz G, Bermúdez A, Valcárcel D, Rovira M, Serrano D, Caballero D, Espigado L, Morgades M, Heras I, Solano C, Duarte R, Barrenetxea C, García-Noblejas A, Díez-Martin JL, Iriondo A, Carreras E, Sierra J, Sanz MA, Ribera JM. **Biol Blood Marrow Transplant**. 2010 Jul; 16(7):957-66.

Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFN γ CD8 $^{+}$ and CD4 $^{+}$ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection Tormo N, Solano C, Benet I, Nieto J, **de la Cámara R, García-Noblejas A**, Clari MA, Chilet M, López J, Hernández-Boluda JC, Remigia MJ, Navarro D.. **J Med Virol**. 2010 Jul; 82(7):1208-15.

Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absence of clinically suspected infection. Muñoz-Cobo B, Solano C, Nieto J, de la Cámara R, Remigia MJ, García-Noblejas A, López J, Benet I, Hernández-Boluda JC, Costa E, Bravo D, Navarro D. **Bone Marrow Transplant**. 2011 Jan 10.

AÑO 2.009

Optimal mobilization method and CD34+ dose calculation for autologous PBSC transplant in myeloma patients: two important unresolved questions. **Alegre A**. **Bone Marrow Transplant**. 2009 Apr; 43(8):593-5

Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Blanes M, de la Rubia J, Lahuerta JJ, González JD, Ribas P, Solano C, **Alegre A**, Sanz MA. **Leuk Lymphoma**. 2009 Feb; 50(2):216-22.

Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma Saez AI, García-Cosío M, Sáez AJ, Hernández JM, Sánchez-Verde L, Alvarez D, de la Cueva P, **Arranz R**, Conde E, Grande C, Rodríguez J, Caballero D, Piris MA.. **Leuk Lymphoma**. 2009 Apr; 50(4):571-81

Spanish Lymphoma/ Autologous Bone Marrow Transplant Study Group (GEL-TAMO). Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. Robledo C, García JL, Caballero D, Conde E, **Arranz R**, Flores T, Grande C, Rodríguez J, García E, Sáez AI, González M, Gutiérrez NC, Piris MA, Hernández JM; **Cancer** 2009 Aug 15; 115(16):3728-37.

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, **Stegmann JL**, Stenke L, Porkka K. **Leukemia**. 2009 Aug;23(8):1398-405. Epub 2009 Mar 19.

Clinical perspective on evolving CML guidelines for monitoring TKI response **Stegmann JL**:. In **Preview Press**. New York NY 10036; 2009.

IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y, Investigator : **JL Stegmann**:. **Blood** 2009, 111(8):4022-4028.

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. S. Mustjoki, M. Ekblom, T. P. Arstila, I. Dybedal, P. K. Epling-Burnette, F. Guilhot, H. Hjorth-Hansen, M. Hoglund, P. Kovanen, T. Laurinli, J. Liesveld, R. Paquette, J. Pinilla-Ibarz, A. Rauhala, N. Shah, B. Simonsson, M. Sinisalo, **J.L. Stegmann**, L. Stenke, and K. Porkka. **Leukemia** 23 (8):1398-1405, 2009.

Dasatinib en pacientes con leucemia mieloide crónica en fase crónica y resistencia o intolerancia a Imatinib. **Stegmann JL**. **Med Clin. Barc**. Monografías 9, 12-16, 2009.

Multiple pretibial cutaneous relapses of acute myeloblastic leukemia after allogeneic bmt. Suárez A, Goiriz R, Domínguez-Fernández I, **Gómez-García de Soria V**, **Cámara R**, Fraga J, García-Diez A. **Bone Marrow Transplant**. 2009 May; 43(10):819-20. E pub 2009 Han 26.

Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: comparison of presenting clinical characteristics and response to treatment. Alvarez-Larrán A, Del Río-Garma J, Pujol M, de la Rubia J, Hernández-Jodra M, Borrell M, González-Porras JR, García-Gala JM, Viejo A, Enríquez L, Arbona C, García-Erce JA, **Noblejas AG**, Pereira A. **Ann Hematol**. 2009 Feb 11.

AÑO 2.008

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García-Laraña J, Martínez-Martínez R, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernández-Ruiz B, García-Frade J, Rivas-González C, **Alegre A**, Bladé J, San Miguel JF. **J Clin Oncol**. 2008 Dec 10; 26(35):5775-82.

Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells. Mod Pathol Camacho FI, Bellas C, Corbacho C, Caleo A, Arranz-Sáez R, Cannata J, Menárguez J, Sánchez-Verde L, González-Camacho L, Pérez-Martín ME, Martínez-González MA, Álvaro T, Mollejo M, Ruíz-Marcellán C, Montalbán C, Piris MA. 2011, *Muy*; 24(5):698-707. E pub 2011 Jan 14

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, **Loscertales J**, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. **J Clin Oncol**. 2009 Sep 10; 27(26):4378-84.

Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia. Cuesta-Mateos C, López-Giral S, Alfonso-Pérez M, de Soria VG, **Loscertales J**, Guasch-Vidal S, Beltrán AE, Zapata JM, Muñoz-Calleja C. **Exp Hematol**. 2010 Sep;38(9):756-64. e1-4

Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, del Rey M, **Arranz E**, Ramiro S, Font P, González O, Renedo M, Cervera J, Such E, Sanz GF, Luño E, Sanzo C, González M, Calasanz MJ, Mayans J, García-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yañez L, Muruzabal MJ, Gómez-Beltrán E, Andreu R, León P, Gómez V, Sanz A, Casasola N, Moreno E, **Alegre A**, Martín ML, Pedro C, Serrano S, Florensa L, Solé F. **Haematologica**. 2008 Jul; 93(7):1001-8.

PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Albajar M, Gutierrez P, Richard C, Rosa-Garrido M, Gómez-Casares MT, **Stegmann JL**, León J, Delgado MD. **Cancer Lett**. 2008 Nov 8;270(2):328-36